FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:481 August 18, 1994 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Wood, M. J.

To the Editor: In their report on the treatment of acute herpes zoster (March 31 issue),¹ Wood et al. state that "intravenous and oral acyclovir in immunocompetent patients are associated with significant improvements in the rate of healing and the severity of the acute pain of herpes zoster," and that "because the benefits of acyclovir therapy during the acute phase are established, it was considered unethical to include a placebo group." Although the authors report a well-executed study, we would like to put these two statements into perspective.

It is true that in each of the published controlled studies, including . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.